YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome

Brian Kornblit; T Wang; S J Lee; S R Spellman; X Zhu; K Fleischhauer; Catharina Müller; M R Verneris; Klaus Müller; Julia Sidenius Johansen; Lars Vindeløv; Peter Garred

doi:10.1038/bmt.2016.192

YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome

Brian Kornblit, T Wang, S J Lee, S R Spellman, X Zhu, K Fleischhauer, Catharina Müller, M R Verneris, Klaus Müller, Julia Sidenius Johansen, Lars Vindeløv, Peter Garred

Department of Clinical Medicine

1 Citation (Scopus)

Abstract

YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor plasma YKL-40 concentrations in patients with AML (n=624) or myelodysplastic syndrome (n=157) treated with allogeneic hematopoietic cell transplantation (HCT). In recipients, the plasma YKL-40 concentrations were increased when the HCT-comorbidity index was ⩾5 (P=0.028). There were no significant associations between plasma YKL-40 concentrations in recipients and any outcome measures. In donors with YKL-40 plasma concentrations above the age-adjusted 95th percentile, a trend toward increased grade II-IV acute GvHD in recipients was observed (adjusted hazard ratio 1.39 (95% confidence interval 1.00-1.94), P=0.050), with no significant associations with overall survival, treatment-related mortality or relapse. In conclusion, our study shows that YKL-40 does not aid risk stratification of patients undergoing allogeneic HCT, but suggests that YKL-40 may aid donor selection when multiple, otherwise equal, donors are available.

Original language	English
Journal	Bone
Volume	51
Issue number	12
Pages (from-to)	1556-1560
Number of pages	5
ISSN	8756-3282
DOIs	https://doi.org/10.1038/bmt.2016.192
Publication status	Published - 1 Dec 2016

Keywords

Journal Article

Access to Document

10.1038/bmt.2016.192

Cite this

@article{1ba7d65207834d22b45354d2946c746f,

title = "YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome",

abstract = "YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor plasma YKL-40 concentrations in patients with AML (n=624) or myelodysplastic syndrome (n=157) treated with allogeneic hematopoietic cell transplantation (HCT). In recipients, the plasma YKL-40 concentrations were increased when the HCT-comorbidity index was ⩾5 (P=0.028). There were no significant associations between plasma YKL-40 concentrations in recipients and any outcome measures. In donors with YKL-40 plasma concentrations above the age-adjusted 95th percentile, a trend toward increased grade II-IV acute GvHD in recipients was observed (adjusted hazard ratio 1.39 (95% confidence interval 1.00-1.94), P=0.050), with no significant associations with overall survival, treatment-related mortality or relapse. In conclusion, our study shows that YKL-40 does not aid risk stratification of patients undergoing allogeneic HCT, but suggests that YKL-40 may aid donor selection when multiple, otherwise equal, donors are available.",

keywords = "Journal Article",

author = "Brian Kornblit and T Wang and Lee, {S J} and Spellman, {S R} and X Zhu and K Fleischhauer and Catharina M{\"u}ller and Verneris, {M R} and Klaus M{\"u}ller and Johansen, {Julia Sidenius} and Lars Vindel{\o}v and Peter Garred",

year = "2016",

month = dec,

day = "1",

doi = "10.1038/bmt.2016.192",

language = "English",

volume = "51",

pages = "1556--1560",

journal = "Bone",

issn = "8756-3282",

publisher = "Elsevier",

number = "12",

}

TY - JOUR

T1 - YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome

AU - Kornblit, Brian

AU - Wang, T

AU - Lee, S J

AU - Spellman, S R

AU - Zhu, X

AU - Fleischhauer, K

AU - Müller, Catharina

AU - Verneris, M R

AU - Müller, Klaus

AU - Johansen, Julia Sidenius

AU - Vindeløv, Lars

AU - Garred, Peter

PY - 2016/12/1

Y1 - 2016/12/1

N2 - YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor plasma YKL-40 concentrations in patients with AML (n=624) or myelodysplastic syndrome (n=157) treated with allogeneic hematopoietic cell transplantation (HCT). In recipients, the plasma YKL-40 concentrations were increased when the HCT-comorbidity index was ⩾5 (P=0.028). There were no significant associations between plasma YKL-40 concentrations in recipients and any outcome measures. In donors with YKL-40 plasma concentrations above the age-adjusted 95th percentile, a trend toward increased grade II-IV acute GvHD in recipients was observed (adjusted hazard ratio 1.39 (95% confidence interval 1.00-1.94), P=0.050), with no significant associations with overall survival, treatment-related mortality or relapse. In conclusion, our study shows that YKL-40 does not aid risk stratification of patients undergoing allogeneic HCT, but suggests that YKL-40 may aid donor selection when multiple, otherwise equal, donors are available.

AB - YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor plasma YKL-40 concentrations in patients with AML (n=624) or myelodysplastic syndrome (n=157) treated with allogeneic hematopoietic cell transplantation (HCT). In recipients, the plasma YKL-40 concentrations were increased when the HCT-comorbidity index was ⩾5 (P=0.028). There were no significant associations between plasma YKL-40 concentrations in recipients and any outcome measures. In donors with YKL-40 plasma concentrations above the age-adjusted 95th percentile, a trend toward increased grade II-IV acute GvHD in recipients was observed (adjusted hazard ratio 1.39 (95% confidence interval 1.00-1.94), P=0.050), with no significant associations with overall survival, treatment-related mortality or relapse. In conclusion, our study shows that YKL-40 does not aid risk stratification of patients undergoing allogeneic HCT, but suggests that YKL-40 may aid donor selection when multiple, otherwise equal, donors are available.

KW - Journal Article

U2 - 10.1038/bmt.2016.192

DO - 10.1038/bmt.2016.192

M3 - Journal article

C2 - 27427920

SN - 8756-3282

VL - 51

SP - 1556

EP - 1560

JO - Bone

JF - Bone

IS - 12

ER -

YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome

Abstract

Keywords

Access to Document

Fingerprint

Cite this